A detailed history of Legal & General Group PLC transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 4,910 shares of VYGR stock, worth $37,954. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,910
Previous 4,910 -0.0%
Holding current value
$37,954
Previous $45,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$7.15 - $10.84 $4,304 - $6,525
602 Added 13.97%
4,910 $45,000
Q3 2023

Nov 14, 2023

SELL
$7.55 - $11.25 $3,095 - $4,612
-410 Reduced 8.69%
4,308 $33,000
Q2 2023

Aug 14, 2023

BUY
$6.94 - $13.99 $32,742 - $66,004
4,718 New
4,718 $54,000
Q2 2021

Aug 12, 2021

SELL
$3.94 - $5.44 $18,230 - $25,170
-4,627 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$4.61 - $9.04 $3,614 - $7,087
784 Added 20.4%
4,627 $22,000
Q3 2020

Nov 13, 2020

SELL
$10.01 - $13.75 $10,110 - $13,887
-1,010 Reduced 20.81%
3,843 $41,000
Q2 2020

Aug 14, 2020

BUY
$8.05 - $14.21 $313 - $554
39 Added 0.81%
4,853 $61,000
Q1 2020

May 14, 2020

SELL
$6.8 - $14.66 $5,766 - $12,431
-848 Reduced 14.98%
4,814 $44,000
Q4 2019

Feb 13, 2020

BUY
$12.82 - $16.85 $11,730 - $15,417
915 Added 19.28%
5,662 $79,000
Q2 2019

Aug 14, 2019

BUY
$19.18 - $27.88 $20,925 - $30,417
1,091 Added 29.84%
4,747 $130,000
Q1 2019

May 15, 2019

BUY
$8.0 - $19.66 $3,656 - $8,984
457 Added 14.29%
3,656 $70,000
Q2 2018

Aug 10, 2018

BUY
$16.76 - $23.92 $4,424 - $6,314
264 Added 8.99%
3,199 $63,000
Q1 2018

May 17, 2018

SELL
$16.16 - $31.31 $23,028 - $44,616
-1,425 Reduced 32.68%
2,935 $55,000
Q4 2017

Feb 13, 2018

BUY
$12.26 - $25.88 $53,453 - $112,836
4,360
4,360 $72,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $299M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.